Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of ZA-302 is to determine the effects of Androxal on morning testosterone and
reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism
(confirmed morning T<300 ng/dL) and normal sperm concentration, compared to changes with
placebo. Subjects must not have previously been treated with testosterone products within the
last 6 months.